<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01703390</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_ERCC1</org_study_id>
    <secondary_id>2011-003217-41</secondary_id>
    <nct_id>NCT01703390</nct_id>
  </id_info>
  <brief_title>Biomarker Directed Treatment in Metastatic Colorectal Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is being mounted to assess whether treatment assignment by ERCC-1 gene
      expression status suggests better clinical results from historical experience in metastatic
      colorectal cancer (mCRC). In wild type KRAS mCRC patients treated with either FOLFOX or
      FOLFIRI in combination with cetuximab the median response rate is approximately 60-65%.
      Biomarker directed treatment in this study may demonstrate that patients with low ERCC-1
      treated with FOLFOX and cetuximab, and those with high ERCC-1 treated with FOLFIRI and
      cetuximab, will improve response rate to 70-75%. KRAS wild type patients will be treated with
      6 cycles of one of the following regimens chosen for optimization based on patient
      characteristics (primary treatment phase). Patients with ERCC-1 &lt; 1.7 relative gene
      expression of ERCC-1 over ß-actin (ERCC-1 low) will be assigned to treatment with mFOLFOX6 in
      combination with Cetuximab. Patients with ERCC-1 gene expression &gt; 1.7 relative gene
      expression of ERCC-1 over over ß-actin (ERCC-1 high) will be assigned to treatment with
      FOLFIRI in combination with Cetuximab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>5 years</time_frame>
    <description>Treatment response according to Response Evaluation Criteria In Solid Tumors [RECIST]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>5 years</time_frame>
    <description>To establish the feasibility of conducting a biomarker based trial of ERCC-1, in wt KRAS mCRC patients in the cooperative group setting to assess progression free survival (PFS) and overall survival (OS) intients with biomarker directed treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>5 years</time_frame>
    <description>Description of group differences between ERCC-1 low and ERCC-1 high patients with respect to response rate, PFS and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient characteristics</measure>
    <time_frame>5 years</time_frame>
    <description>Description of group differences between ERCC-1 low and ERCC-1 high patients with respect to KRAS status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary resection rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular markers for toxicity</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Analysis of occuring adverse events during the study treatment according to Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>ERCC-1 low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modifiedFOLFOX6 + Cetuximab oxaliplatin 85 mg/m2 on day 1, 15 q d29 for 6 cycles folinic acid (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus day 1 + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ERCC-1 high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI + Cetuximab irinotecan 180 mg/m² on day 1, 15 q d29 for 6 cycles folinic acid (FA)400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI + Cetuximab</intervention_name>
    <arm_group_label>ERCC-1 high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modifiedFOLFOX6 + Cetuximab</intervention_name>
    <arm_group_label>ERCC-1 low</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.1 Inclusion criteria for pre-screening phase:

          -  Untreated advanced metastatic colorectal cancer patients

          -  Adequate tissue to evaluate for genotyping (10 x 10µm thick formalin fixed paraffin
             embedded tissue sections and one corresponding HE stained slide or a FFPE tumor block)

        1.2 Inclusion criteria for treatment phase:

        Patients must fulfill all criteria listed below prior to enrolment in the study:

          -  Untreated wild-type KRAS metastatic colorectal cancer

          -  Previous adjuvant therapy must have been completed &gt; 6 months before therapy
             initiation on this study

          -  Age &gt;18 years

          -  Measureable disease with CT or MRI

          -  ECOG performance status of 0-2

          -  Adequate organ function

               -  Hematologic:

                    -  Absolute neutrophil count &gt; 1,500/µL

                    -  Hemoglobin &gt;9 mg/dl

                    -  Platelet count &gt;100,000 /µl

               -  Renal:

                    -  Serum creatinine &lt;1.5 x Upper limit of normal (UPN) or estimated clearance &gt;
                       30 ml/min

               -  Hepatic:

                    -  Serum bilirubin &lt; 1.5 mg/dl

        Exclusion Criteria:

          -  Creatinine clearance below 30 ml/min

          -  Patients with a history of other malignancies within 2 years prior to study entry,
             except for adequately treated carcinoma in situ of the cervix; basal or squamous cell
             skin cancer; low grade, early stage localized prostate cancer treated surgically with
             curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with
             curative intent.

          -  Patients with a history of severe cardiac disease; e.g. NYHA Functional Class III or
             IV heart failure, myocardial infarction within 6 months, ventricular tachyarrhythmias
             requiring ongoing treatment, or unstable angina.

          -  Other known co-morbidity with the potential to dominate survival

          -  Hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any
             of the applied drugs

          -  Pregnant or breast feeding women

          -  Any co-existing medical or psychological condition that would preclude participation
             in the study or compromise ability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Winder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LKH Feldkirch, Interne E</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Greil, MD</last_name>
    <phone>004357255</phone>
    <phone_ext>25801</phone_ext>
    <email>r.greil@salk.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>AKH Linz, Innere Medizin 3, Zentrum für Hämatologie und medizinische Onkologie</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Fridrik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie</name>
      <address>
        <city>Kufstein</city>
        <state>Tirol</state>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>August Zabernigg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LKH Feldkirch, Interne E</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Winder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LKH Bludenz Innere Medizin</name>
      <address>
        <city>Bludenz</city>
        <zip>6700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Othmar Thurnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LKH Bregenz</name>
      <address>
        <city>Bregenz</city>
        <zip>6900</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Franz X Schmid, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KH Dornbirn, Innere Medizin</name>
      <address>
        <city>Dornbirn</city>
        <zip>6850</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guntram Winder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helmuth Samonigg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LKH Hohenems, Interne Intensivmedizin</name>
      <address>
        <city>Hohenems</city>
        <zip>6845</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Günter Höfle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus d. Barmherzigen Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Petzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Greil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien, Univ.Klinik für Innere Medizin I, Abteilung für Onkologie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerald Prager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2012</study_first_submitted>
  <study_first_submitted_qc>October 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2012</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>mCRC</keyword>
  <keyword>ERCC-1</keyword>
  <keyword>ERCC1</keyword>
  <keyword>AGMT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

